Navigation Links
Dutch Biotech Company Pepscan Appoints New CEO
Date:12/2/2009

LELYSTAD, The Netherlands, December 2 /PRNewswire/ -- Pepscan Holding NV, the Netherlands based biotechnology company focusing on protein mimicking technology for the generation of immune therapeutics today announced that it has appointed Wim E.M. Mol, Ph.D. as new Chief Executive Officer.

Dr. Mol will be responsible for all of Pepscans corporate functions and the overall management and strategic direction of the company. He brings to Pepscan more than 20 years of management experience in the international pharmaceutical industry.

Dr. Mol was previously at Schering Plough where he was Vice-President responsible for the global scientific development and commercial strategy of a Phase III project in an alliance with a subsidiary of Merck-Serono. Dr. Mol commented, "I look forward to working with the highly professional and talented team at Pepscan. It is exciting to contribute to the creation of new therapeutic antibodies against currently intractable targets, using manmade mimics of the biologically relevant part of the target".

"Dr. Mol has tremendous experience that will be very valuable to Pepscan. He has held multiple executive level roles, including general management positions in the USA and other countries, and executive director positions in global marketing and alliance management. With his track record as a result-driven leader, I am confident that he will bring Pepscan to the next level as a leading company in the field of protein mimicry, fully exploiting its proprietary CLIPS(TM) technology", said Wim Jongen, Chairman of the Board.

Joost van Bree Ph.D., who has been fully supportive of the change in business focus towards CLIPS based technology has decided to step down as CEO and continue to work on the development of therapeutic vaccines. Mr. Jongen said, "Joost has been instrumental in broadening the company portfolio and creating the momentum for growth. His contribution has been enormous and in this new phase of the company, he will continue to focus on the successful development of the proprietary pipeline of the therapeutic vaccine portfolio".

Notes to the editor:

About Pepscan

Pepscan Holding NV is a privately owned company based in Lelystad, the Netherlands. The company focuses on immunotherapy. It has developed a pipeline of therapeutic vaccine and antibody programs, of which the most advanced is in Phase II clinical testing. Pepscans proprietary CLIPS(TM) technology has been proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs. For more information visit http://www.pepscan.com.

About CLIPS(TM) technology

CLIPS(TM) (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains and hitherto have been used in antibody and vaccine programs to create superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).

SOURCE Pepscan Holding N.V.


'/>"/>
SOURCE Pepscan Holding N.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
2. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
3. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
4. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
5. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
6. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
7. Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
8. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
11. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 On Thursday, March 23, ... 5,817.69, down 0.07%; the Dow Jones Industrial Average edged ... 500 closed at 2,345.96, marginally dropping 0.11%. US markets ... green, 4 sectors finished in red, and 1 sector ... initiated reports coverage on the following Biotechnology equities: BioDelivery ...
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... selected by the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® ... annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished in ...
(Date:3/23/2017)... -- In today,s pre-market research, Stock-Callers.com takes ... industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. ... Regulus Therapeutics Inc. (NASDAQ: RGLS ). On ... rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about ... ...
Breaking Biology Technology:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):